{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:29:27Z","timestamp":1781252967535,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Psoriatic arthritis (PsA) is a chronic, immune-mediated, spondyloarthropathy characterised by musculoskeletal signs and symptoms with associated joint pain and tenderness. The average worldwide PsA prevalence is 133\/100,000, while in the Italian population is 90\u2013420\/100,000.<\/jats:p><jats:p>Traditionally, nonsteroidal anti-inflammatory drugs, glucocorticoid, and disease-modifying antirheumatic drugs have been used in the treatment of PsA. However, for those patients who are not adequately controlled with conventional therapies, the new biologics compounds represent a valid option. Biologic therapies have been shown to be more effective but also more expensive than conventional systemic treatments. Based on the CHRONOS study, the economic analyses presented in this paper aim to assess the annualised direct costs and the cost-per-responder of biologics in a real-world context assuming the Italian National Health System perspective.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The economic assessments were carried out on the overall cohort of patients, and on the tumour necrosis factor alpha inhibitors (TNFi) and the secukinumab subgroup, the most prescribed biologic therapies within the CHRONOS study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The annual economic impact of PsA in the overall group was \u20ac12,622, \u20ac11,725 in the secukinumab subgroup, and \u20ac12,791 in the TNFi subgroup. Biologics absorbed the main expenditure costs in the treatment of PsA accounting for about the 93% of total costs. At 6\u2009months, secukinumab performed better in all the considered outcomes: cost-per-responder according to EULAR DAS28 and ACR50 response criteria were \u20ac12,661- \u20ac28,975, respectively, while they were \u20ac13,356 - \u20ac33,368 in the overall cohort and \u20ac13,138 - \u20ac35,166 in the TNFi subgroup. At 12\u2009months secukinumab remained the subgroup with the lowest cost-per-responder ratio in EULAR DAS28 and ACR50 response criteria, while TNFi subgroup was the lowest one considered the ACR20.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Despite some potential methodological limitations, our cost-per-response analysis provides physicians and payers additional insights which can complement the traditional risk-benefit profile assessment and drive treatment decisions.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12913-022-08954-8","type":"journal-article","created":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T00:04:34Z","timestamp":1671235474000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A real-world economic analysis of biologic therapies for psoriatic arthritis in Italy: results of the CHRONOS observational longitudinal study"],"prefix":"10.1186","volume":"22","author":[{"given":"Emanuela","family":"Zagni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micol","family":"Frassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppa Pagano","family":"Mariano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Fusaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Lomater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Del Medico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Foti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Limonta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Marchesoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Raffeiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Viapiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Daniela","family":"Grembiale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Guggino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Mazzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Tirri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Perricone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Carlo","family":"Sarzi Puttini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Zullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Simoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Fiocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Orsenigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,16]]},"reference":[{"key":"8954_CR1","doi-asserted-by":"crossref","unstructured":"Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JYM, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol . 2008;58(5):851\u201364.","DOI":"10.1016\/j.jaad.2008.02.040"},{"key":"8954_CR2","doi-asserted-by":"publisher","unstructured":"Eder L, Polachek A, Rosen CF, Chandran V, Cook R, Gladman DD. The development of psoriatic arthritis in patients with psoriasis is preceded by a period of nonspecific musculoskeletal symptoms: a prospective cohort study. Arthritis Rheumatol. 2017;69(3):622\u20139. https:\/\/doi.org\/10.1002\/art.39973.","DOI":"10.1002\/art.39973"},{"key":"8954_CR3","doi-asserted-by":"crossref","unstructured":"Scotti L, Franchi M, Marchesoni A, Corrao G. Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum . 2018;48(1):28\u201334.","DOI":"10.1016\/j.semarthrit.2018.01.003"},{"key":"8954_CR4","doi-asserted-by":"crossref","unstructured":"Prignano F, Rogai V, Cavallucci E, Bitossi A, Hammen V, Cantini F. Epidemiology of psoriasis and psoriatic arthritis in Italy\u2014a systematic review. Curr Rheumatol Rep. 2018;20(7):43","DOI":"10.1007\/s11926-018-0753-1"},{"key":"8954_CR5","doi-asserted-by":"crossref","unstructured":"Kavanaugh A, Mease PJ, Reimold AM, Tahir H, Rech J, Hall S, et al. Secukinumab for Long-term treatment of psoriatic arthritis: a two-year Followup from a phase III, randomized, double-blind placebo-controlled study. Arthritis Care Res (Hoboken). 2017;69(3):347\u201355.","DOI":"10.1002\/acr.23111"},{"issue":"3","key":"8954_CR6","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S, De Wit M, Cutolo M, Dougados M, et al. European league against rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499\u2013510 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26644232\/.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8954_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/acr.23789","volume":"7","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Care Res. 2019;7(1):2\u201329 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30499259\/.","journal-title":"Arthritis Care Res"},{"issue":"5","key":"8954_CR8","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, et al. Group for Research and Assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060\u201371 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26749174\/.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"8954_CR9","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40257-013-0030-z","volume":"14","author":"CS Ahn","year":"2013","unstructured":"Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR. Cost effectiveness of biologic therapies for plaque psoriasis. Am J Clin Dermatol. 2013;14(4):315\u201326 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23696234\/.","journal-title":"Am J Clin Dermatol"},{"key":"8954_CR10","doi-asserted-by":"crossref","unstructured":"D\u2019Angiolella LS, Cortesi PA, Lafranconi A, Micale M, Mangano S, Cesana G, et al. Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review [Internet]. Vol. 36, PharmacoEconomics. Springer International Publishing; 2018 [cited 2020 Nov 6]. p. 567\u201389. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29441473\/","DOI":"10.1007\/s40273-018-0618-5"},{"issue":"4","key":"8954_CR11","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jval.2016.12.003","volume":"20","author":"A Makady","year":"2017","unstructured":"Makady A, ten Ham R, de Boer A, Hillege H, Klungel O, Goettsch W. Policies for use of real-world data in health technology assessment (HTA): a comparative study of six HTA agencies. Value Heal. 2017;20(4):520\u201332 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28407993\/.","journal-title":"Value Heal"},{"issue":"9","key":"8954_CR12","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/pds.4297","volume":"26","author":"ML Berger","year":"2017","unstructured":"Berger ML, Sox H, Willke RJ, Brixner DL, Eichler HG, Goettsch W, et al. Good practices for real-world data studies of treatment and\/or comparative effectiveness: recommendations from the joint ISPOR-ISPE special task force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017;26(9):1033\u20139 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28913966\/.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"8954_CR13","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/j.1468-3083.2009.03159.x","volume":"23","author":"MA Radtke","year":"2009","unstructured":"Radtke MA, Reich K, Blome C, Rustenbach S, Augustin M. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatology Venereol. 2009;23(6):683\u201391 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19309433\/.","journal-title":"J Eur Acad Dermatology Venereol"},{"key":"8954_CR14","doi-asserted-by":"crossref","unstructured":"Christophers E, Barker J, Griffiths C, Daud\u00e9n E, Milligan G, Molta C, et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol. 2010;24(5):548\u201354.","DOI":"10.1111\/j.1468-3083.2009.03463.x"},{"key":"8954_CR15","doi-asserted-by":"crossref","unstructured":"Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum. 1997;40(10):1868\u201372.","DOI":"10.1002\/art.1780401021"},{"key":"8954_CR16","doi-asserted-by":"crossref","unstructured":"Ali Y, Tom BDM, Schentag CT, Farewell VT, Gladman DD. Improved survival in psoriatic arthritis with calendar time. Arthritis Rheum. 2007;56(8):2708\u201314.","DOI":"10.1002\/art.22800"},{"key":"8954_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s41927-022-00284-w","volume":"6","author":"D Colombo","year":"2022","unstructured":"Colombo D, Frassi M, Pagano Mariano G, Fusaro E, Lomater C, Del Medico P, et al. Real-world evidence of biologic treatments in psoriatic arthritis in Italy: results of the CHRONOS (EffeCtiveness of biologic treatments for psoriatic artHRitis in Italy: an ObservatioNal lOngitudinal study of real-life clinical practice) observational lo. BMC Rheumatol. 2022;6:57. https:\/\/doi.org\/10.1186\/s41927-022-00284-w.","journal-title":"BMC Rheumatol"},{"key":"8954_CR18","doi-asserted-by":"crossref","unstructured":"Salaffi F, Ciapetti A, Carotti M, Gasparini S, Gutierrez M. Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world. Biomed Res Int. 2014;2014:528105.","DOI":"10.1155\/2014\/528105"},{"issue":"9999","key":"8954_CR19","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137\u201346 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26135703\/.","journal-title":"Lancet"},{"key":"8954_CR20","doi-asserted-by":"crossref","unstructured":"Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, Van Der Heijde D, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329\u201339.","DOI":"10.1056\/NEJMoa1412679"},{"issue":"5","key":"8954_CR21","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1136\/annrheumdis-2017-211568","volume":"77","author":"P Nash","year":"2018","unstructured":"Nash P, Ohson K, Walsh J, Delev N, Nguyen D, Teng L, et al. Early and sustained efficacy with apremilast monotherapy in biological-na\u00efve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Ann Rheum Dis. 2018;77(5):690\u20138 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29343507\/.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"8954_CR22","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40257-019-00490-2","volume":"21","author":"A Chiricozzi","year":"2020","unstructured":"Chiricozzi A, Burlando M, Caldarola G, Conti A, Damiani G, De Simone C, et al. Ixekizumab effectiveness and safety in the treatment of moderate-to-severe plaque psoriasis: a multicenter, retrospective observational study. Am J Clin Dermatol. 2020;21(3):441\u20137 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31786732\/.","journal-title":"Am J Clin Dermatol"},{"key":"8954_CR23","doi-asserted-by":"crossref","unstructured":"Prevoo MLL, Van\u2019T Hof MA, Kuper HH, Van Leeuwen MA, Van De Putte LBA, PLCM VR. Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44\u20138.","DOI":"10.1002\/art.1780380107"},{"key":"8954_CR24","doi-asserted-by":"crossref","unstructured":"Van Gestel AM, Haagsma CJ, Van Riel PLCM. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 1998;41(10):1845\u201350.","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K"},{"key":"8954_CR25","unstructured":"DAS28-EULAR Response criteria [Internet]. Available from: https:\/\/www.das-score.nl\/en\/das-and-das28\/das28-why\/eular-response-criteria. Accessed Dec 2022."},{"issue":"6","key":"8954_CR26","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/art.1780360601","volume":"36","author":"DT Felson","year":"1993","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum. 1993;36(6):729\u201340 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/8507213\/.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"8954_CR27","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American college of rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727\u201335 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/7779114\/.","journal-title":"Arthritis Rheum"},{"key":"8954_CR28","unstructured":"Italian Ministry of Health. Outpatient intervention tariffs. Italian Republic Official Gazette. Chapter n. 23; Supplement n. 8; 28 January 2013. 2013a. p. 27\u201357."},{"key":"8954_CR29","unstructured":"Italian Ministry of Health. Inpatient intervention tariffs. Italian Republic Official Gazette. Chapter n. 23; Supplement n. 8; 28 January 2013.\u00a02013. p. 6\u201323."},{"issue":"2","key":"8954_CR30","first-page":"109","volume":"4","author":"Garattini","year":"2003","unstructured":"Garattini. Duration and costs of general practitioners\u2019 visits: the DYSCO project. Farmeconomia Percorsi Ter. 2003;4(2):109\u201314.","journal-title":"Farmeconomia Percorsi Ter"},{"key":"8954_CR31","unstructured":"National Institute of Statistics of Italy (ISTAT). Inflation rates. Available at: http:\/\/rivaluta.istat.it\/Rivaluta\/. Accessed: Sept 2018."},{"key":"8954_CR32","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.2310\/7750.2009.00021","volume-title":"Journal of cutaneous medicine and surgery","author":"Y Poulin","year":"2009","unstructured":"Poulin Y, Langley R, Teixeira HD, Martel MJ, Cheung S. Biologics in the treatment of psoriasis: clinical and economic overview. In: Journal of cutaneous medicine and surgery, vol. 13. Los Angeles: SAGE PublicationsSage CA; 2009. p. S49\u201357. https:\/\/doi.org\/10.2310\/7750.2009.00021."},{"issue":"5","key":"8954_CR33","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1136\/ard.2008.092767","volume":"68","author":"PJ Mease","year":"2009","unstructured":"Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van Den Bosch F, Wellborne F, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab effectiveness in psoriatic arthritis trial (ADEPT). Ann Rheum Dis. 2009;68(5):702\u20139 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/18684743\/.","journal-title":"Ann Rheum Dis"},{"key":"8954_CR34","doi-asserted-by":"crossref","unstructured":"Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, et al. Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. RMD Open. 2018;4(2) Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30167329\/.","DOI":"10.1136\/rmdopen-2018-000723"},{"key":"8954_CR35","doi-asserted-by":"crossref","unstructured":"Coates LC, Gladman DD, Nash P, Fitzgerald O, Kavanaugh A, Kvien TK, et al. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study 11 medical and health sciences 1117 public health and health services. Arthritis Res Ther. 2018;20(1) Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30526678\/.","DOI":"10.1186\/s13075-018-1773-y"},{"issue":"7","key":"8954_CR36","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/art.40851","volume":"71","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Gladman DD, Collier DH, Ritchlin CT, Helliwell PS, Liu L, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheumatol. 2019;71(7):1112\u201324 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30747501\/.","journal-title":"Arthritis Rheumatol"},{"key":"8954_CR37","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2147\/BTT.S168691","volume":"12","author":"LD Esposti","year":"2018","unstructured":"Esposti LD, Perrone V, Sangiorgi D, Buda S, Andretta M, Rossini M, et al. Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies. Biol Targets Ther. 2018;12:151\u20138 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30518996\/.","journal-title":"Biol Targets Ther"},{"key":"8954_CR38","doi-asserted-by":"crossref","unstructured":"K\u00fcster D, Nast A, Gerdes S, Weberschock T, Wozel G, Gutknecht M, et al. Cost-effectiveness of systemic treatments for moderate-to-severe psoriasis in the German health care setting. Arch Dermatol Res. 2016;308(4):249\u201361.","DOI":"10.1007\/s00403-016-1634-y"},{"key":"8954_CR39","doi-asserted-by":"crossref","unstructured":"Hendrix N, Ollendorf DA, Chapman RH, Loos A, Liu S, Kumar V, et al. Cost-effectiveness of targeted pharmacotherapy for moderate to severe plaque psoriasis. J Manag Care Spec Pharm. 2018;24(12):1210\u20137.","DOI":"10.18553\/jmcp.2018.24.12.1210"},{"issue":"7","key":"8954_CR40","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ad.2016.04.018","volume":"107","author":"R Burgos-Pol","year":"2016","unstructured":"Burgos-Pol R, Mart\u00ednez-Sesmero JM, Ventura-Cerd\u00e1 JM, El\u00edas I, Caloto MT, Casado M. Coste de la psoriasis y artritis psori\u00e1sica en cinco pa\u00edses de Europa: una revisi\u00f3n sistem\u00e1tica. Actas Dermosifiliogr. 2016;107(7):577\u201390 Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27316590\/.","journal-title":"Actas Dermosifiliogr"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-08954-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-022-08954-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-08954-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T05:13:19Z","timestamp":1701580399000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-022-08954-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,16]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["8954"],"URL":"https:\/\/doi.org\/10.1186\/s12913-022-08954-8","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,16]]},"assertion":[{"value":"15 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the amended Declaration of Helsinki. Ethical approval for this study was obtained from each participating site according to Italian Regulation applicable for prospective observational studies.The patients provided written informed consent to their involvement in the study.The study was approved by the Ethic Committee of the coordinating center (A.O.U. Policlinico-Vittorio Emanuele P.O. San Marco, Catania, Italy).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Zagni is an employee of Novartis Farma Italy.Dr. Marchesoni reports grants from Novartis, during the conduct of the study; personal fees from Novartis, Abbvie, Pfizer, Eli Lilly, UCB, Janssen, outside the submitted work.Dr. Zullo is employee of MediNeos Observational Research (Modena, Italy), hired by Novartis Farma Italy, responsible for the design and conduction of the CHRONOS study, as well as scientific support, clinical operations, data management, statistical analysis.Dr. Simoni is employee of MediNeos Observational Research (Modena, Italy), hired by Novartis Farma Italy, responsible for the design and conduction of the CHRONOS study, as well as scientific support, clinical operations, data management, statistical analysis.Dr. Fiocchi is an employee of Novartis Farma Italy.Dr. Orsenigo is an employee of Novartis Farma Italy.Dr. Colombo is a part-time employee of Novartis Farma Italy.No further CoI were declared for all other authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1537"}}